ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2265 • ACR Convergence 2023

    Lupus Damage Index Revision – Item Generation and Reduction Phase

    Burak Kundakci1, Megan Barber2, Ann Clarke2, Sindhu Johnson3, Ian Bruce4 and On behalf of the revised SLE organ damage index (SDI) collaborators4, 1Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, 2University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 3Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 4University of Manchester, Manchester, United Kingdom

    Background/Purpose: The SDI is a robust instrument, but is limited by incomplete items, restricted applicability in paediatric patients, and outdated item definitions1. The SLICC, ACR…
  • Abstract Number: 2223 • ACR Convergence 2023

    Relationship Between Sleep Quality, Disease Activity, and Psychological Factors in Patients with Axial Spondyloarthritis: A Cross Sectional Study

    Srujana Budumuru, Rohini Handa, Sundeep Kumar Upadhyaya, Sirinder Jit Gupta, Meera H Shah, Meera P Shah and Anushka Aggarwal, Indraprastha Apollo Hospital, Delhi, India

    Background/Purpose: Sleep problems are prevalent in 30-70% of patients with axial Spondyloarthritis (SpA), negatively impacting their quality of life. Poor sleep quality in these patients…
  • Abstract Number: 2284 • ACR Convergence 2023

    Effect of Air Pollutant Exposure on Disease Activity of Systemic Lupus Erythematous: A Prospective Longitudinal Study from Korea

    Ji-Hyoun Kang1, Hyemin Jeong2, Sung-Eun Choi2, Dong-Jin Park2, Han Joo Baek3, Hyo-Jin Choi4, Jae Hyun Jung5 and Shin-Seok Lee2, 1Chonnam National University Hospital, Gwangju, South Korea, 2Chonnam National University Medical School & Hospital, Gwangju, South Korea, 3Gil Medical Center, Gachon University College of Medicine, Inchon, South Korea, 4Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea, 5Korea University Ansan Hospital, Ansan-si, South Korea

    Background/Purpose: Exposure to air pollutants is associated with an increased risk of pulmonary and cardiovascular disease and death. Because few studies have investigated the effects…
  • Abstract Number: 2288 • ACR Convergence 2023

    Scoping Literature Review and Focus Groups Interviews to Identify Candidate Domains for the SLE OMERACT Core Domain Set

    Wils Nielsen1, Vibeke Strand2, Lee Simon3, Maya Desai4, Ioannis Parodis5, Alfred Kim6, Daniel Wallace7, Yashaar Chaichian8, Sandra Navarra9, Cynthia Aranow10, Meggan MacKay10, Kimberly Trotter11, Oshrat Tayer-Shifman12, Ali Duarte-Garcia13, Lai-Shan Tam14, Manuel Ugarte-Gil15, Guillermo Pons-Estel16, John Reynolds17, Mandana Nikpour18, Danae Papachristos19, Alberta Hoi20, Alison Hendry21, Juanita Romero-Diaz22, Rosalind Ramsey-Goldman23, Hanan Alrayes24, Ibrahim Almaghlouth25, Aarabi Thayaparan26, Carolina Munoz-Grajales27, Aaron Howe28, Behdin Nowrouzi-Kia28, Melanie Anderson29, Dennisse Bonilla29, Julian Thumboo30, Marta Mosca31, Martin Aringer32, Sindhu Johnson33, Aaron Drucker34, Eric Morand35, Ian Bruce36 and Zahi Touma28, 1University of Toronto, Markham, ON, Canada, 2Stanford University, Portola Valley, CA, 3SDG LLC, West Newton, MA, 4OCAD University, Toronto, ON, Canada, 5Karolinska Institutet, Stockholm, Sweden, 6Washington University School of Medicine, St. Louis, MO, 7Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, 8Stanford University, San Mateo, CA, 9University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, 10Feinstein Institutes for Medical Research, Manhasset, NY, 11University of Chicago, Chicago, IL, 12Meir Medical Center, Raanana, Israel, 13Mayo Clinic, Rochester, MN, 14The Chinese University of Hong Kong, New Territories, China, 15Universidad Cientifica del Sur, Lima, Peru, 16RELESSAR, Rosario, Argentina, 17University of Birmingham, Birmingham, United Kingdom, 18The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, 19Mater Hospital, Brisbane, Australia, 20Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, 21Te Whatu Ora, Counties Manukau District, Middlemore Hospital, Auckland, New Zealand, 22Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 23Northwestern University, Chicago, IL, 24Riyadh Military - Prince Soltan Military Medical City ( PSMMC ) - Olaya, Riyadh, Saudi Arabia, 25King Saud University, Riyadh, Saudi Arabia, 26Schroeder Arthritis Institute, Krembil Research Institute, Markham, ON, Canada, 27UHN/TWH, Toronto, ON, Canada, 28University of Toronto, Toronto, ON, Canada, 29University Health Network, Toronto, ON, Canada, 30Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, 31Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 32Faculty of Medicine TU Dresden, Dresden, Germany, 33Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, 34Women's College Hospital, Toronto, ON, Canada, 35Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, 36University of Manchester, Manchester, United Kingdom

    Background/Purpose: We established the OMERACT SLE Working Group in 2021 which includes over 150 members representing over 25 countries and 5 continents to develop a…
  • Abstract Number: 2289 • ACR Convergence 2023

    Short and Long Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease

    Fadi Kharouf1, Juan Pablo Diaz Martinez2, Dafna Gladman3 and Zahi Touma4, 1University Health Network and University of Toronto, Toronto, ON, Canada, 2Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, 3Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada

    b>Background/Purpose: Patients with pure membranous lupus nephritis (LN) are known to have a different disease course than those with proliferative disease. The aim of this…
  • Abstract Number: 2283 • ACR Convergence 2023

    Anti-SARS-CoV-2 Vaccination Among Patients Living with Systemic Lupus Erythematosus in Sweden: Coverage and Clinical Effectiveness

    Arthur Mageau1, Julia Simard2, Elisabet Svenungsson3 and Elizabeth Arkema4, 1Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden / Internal Medicine Unit, Hopital Bichat, Paris, France, 2Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, 3Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 4Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Real-world data assessing the effectiveness of the anti-SARS-CoV2 vaccination in patients living with systemic lupus erythematosus (SLE) are currently lacking. We aimed to describe…
  • Abstract Number: 2208 • ACR Convergence 2023

    Awareness and Attitudes Regarding Axial Spondyloarthritis Among Non-Rheumatology Physicians in the United States

    William Odell1, Swetha Ann Alexander2, Nicolas Page3, Narinder Maheshwari4 and Abhijeet Danve5, 1Yale University, Wethersfield, CT, 2University of Utah Health, Salt Lake City, UT, 3Yale University, New Haven, CT, 4UCONN Health, Farmington, CT, 5Yale University School of Medicine, Glastonbury, CT

    Background/Purpose: Average diagnostic delay for axial spondyloarthritis (axSpA) is 7 to 10 years. Lack of timely referral of inflammatory back pain (IBP) patients by non-rheumatology…
  • Abstract Number: 2211 • ACR Convergence 2023

    A Two-year Comparison of Back Pain and Morning Stiffness in Axial Spondyloarthritis and Non-axial Spondyloarthritis Chronic Back Pain Patients in the Spondyloarthritis Caught Early (SPACE) Cohort

    Ana Bento da Silva1, Miranda Van Lunteren2, Mary Lucy marques3, Karen Fagerli4, Sofia Ramiro5, Désirée van der Heijde5 and Floris Van Gaalen2, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, 3Leiden University Medical Center; Centro Hospitalar e Universitário de Coimbra (Department of Rheumatology), Coimbra, Portugal, 4Diakonhjemmet Hospital, Oslo, Norway, 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Treatment of axial spondyloarthritis (axSpA) has been shown to improve symptoms of the disease such as back pain (BP) and morning stiffness (MS). As…
  • Abstract Number: 2258 • ACR Convergence 2023

    Brain Activity Patterns and Behavioural Performance in SLE Patients During a Spatial Working Memory and Sustained Attention Task

    Michelle Barraclough1, Shane McKie2, Alex Kafkas2, Ben Parker3, Juan Pablo Diaz Martinez4, Andrea Knight5, Kathleen Bingham1, Jiandong Su1, Mahta Kakvan6, Carolina Munoz-Grajales7, Carmela Tartaglia8, Lesley Ruttan9, Joan Wither1, Dennisse Bonilla1, Daniela Montaldi2, Rebecca Elliott2, Patti Katz10, Dorcas Beaton11, Robin Green9, Ian Bruce2 and Zahi Touma12, 1University Health Network, Toronto, ON, Canada, 2University of Manchester, Manchester, United Kingdom, 3Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, 4Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, 5The Hospital for Sick Children, Toronto, ON, Canada, 6University Health Network, University of Toronto, Toronto, ON, Canada, 7UHN/TWH, Toronto, ON, Canada, 8Krembil Brain Institute, University Health Network, University of Toronto, Toronto, ON, Canada, 9University Health Network, Toronto Rehabilitation Institute, Toronto, ON, Canada, 10University of California San Francisco, San Rafael, CA, 11Institute for Work & Health, Toronto, ON, Canada, 12University of Toronto, Toronto, ON, Canada

    Background/Purpose: Cognitive impairment (CI) is a significant problem in SLE but there is a disconnect between objective and subjective CI. This makes it difficult to…
  • Abstract Number: 2212 • ACR Convergence 2023

    Interpretation of Disease-specific Questionnaires on Disease Activity, Functional Capacity and Quality of Life in Daily Practice in Axial Spondyloarthritis

    Styliani Tsiami1, Kalliopi Klavdianou2, Imke Redeker3, Yaren Elif Özdemir4, Philipp Sewerin1, David Kiefer1, Ioana Andreica5, Uta Kiltz6 and Xenofon Baraliakos4, 1Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, 2Asklepieion' General Hospital, Department of Rheumatology, Voula, Kaisariani Athens, Greece, 3Ruhr Universität Bochum, Bochum, Germany, 4Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 5Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 6Rheumazentrum Ruhrgebiet, Herne, Germany

    Background/Purpose: In axial spondyloarthritis (axSpA), assessment of disease activity and physical function in clinical studies relies on patient-reported outcomes (PRO) such as patient's global, BASDAI,…
  • Abstract Number: 2218 • ACR Convergence 2023

    Exploring Metabolite Markers Associated with Treatment Response of Biologic Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis Patients

    John Koussiouris1, Nikita Looby1, Max Kotlyar2, Vathany Kulasingam3, Igor Jurisica4, Ashish J Mathew5, Proton Rahman6 and Vinod Chandran7, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 2Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, 3Department of Laboratory Medicine and Pathobiology, University of Toronto and Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, 4Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, 5Christian Medical College, Vellore, India, 6Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, 7Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: The use of biologic disease-modifying anti-rheumatic drugs (bDMARDS) is the current standard of care for severe diseases like psoriatic arthritis (PsA) which affects approximately…
  • Abstract Number: 2222 • ACR Convergence 2023

    Association Spondyloarthritis and Inflammatory Bowel Disease, More Severe Diseases on Both Sides

    Juliane Michel1, Clément Prati2, Lucine Vuitton3, Eric Toussirot4, Charline Vauchy5, Daniel Wendling6 and frank Verhoeven2, 1Rheumatology, CHU Besancon, Besançon, France, 2Service de rhumatologie, CHU de Besançon, Besançon, France, 3Gastroenterology, CHU Besancon, Besançon, France, 4University Hospital of Besancon, Besançon, France, 5INSERM CIC-1431, Besançon, France, 6Besançon University Hospital, Besançon, France

    Background/Purpose: There is a pathophysiological link between spondyloarthritis (SpA) and Inflammatory Bowel Disease (IBD), so that 10% of IBD is estimated to have SpA and…
  • Abstract Number: 2268 • ACR Convergence 2023

    Mental Illness and Outcomes of COVID-19 in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study

    Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan

    Background/Purpose: Poor COVID-19 outcomes in patients with systemic lupus erythematosus (SLE) has been found to be associated with glucocorticoid dose, male sex, older age, mycophenolate,…
  • Abstract Number: 2275 • ACR Convergence 2023

    Lupus Low Disease Activity State Ameliorates the Poor Prognosis in Lupus Nephritis Patients with anti-Sm Autoantibody

    Chak Kwan Cheung1, Chak Sing Lau2 and Shirley Chiu Wai Chan3, 1Divison of Rheumatology and Clinical Immunology, Queen Mary Hospital, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, 2University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, 3Divison of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: Anti-Sm autoantibody has been a known specific biomarker of systemic lupus erythematosus (SLE). There have been reports about its correlation with higher disease activity,…
  • Abstract Number: 2296 • ACR Convergence 2023

    Association Between EQ-5D-5L and SLEDAI Scores in Patients with Systemic Lupus Erythematosus in the United States and Europe: A Real-world Survey

    Ebuwa Igho-Osagie1, Rezaul Khandker1, Jack Milligan2, Emily Goddard2 and Sophie Barlow2, 1Merck & Co. Inc., Rahway, NJ, 2Adelphi Real World, Bollington, United Kingdom

    Background/Purpose: The EQ-5D-5L is validated for estimating health related quality of life (HRQoL) across a variety of different disease areas, including rheumatic diseases. However, its…
  • « Previous Page
  • 1
  • …
  • 344
  • 345
  • 346
  • 347
  • 348
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology